Related references
Note: Only part of the references are listed.Polycomb-Dependent H3K27me1 and H3K27me2 Regulate Active Transcription and Enhancer Fidelity
Karin J. Ferrari et al.
MOLECULAR CELL (2014)
EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity
Junli Yan et al.
BLOOD (2013)
EZH2 mutations are frequent and represent an early event in follicular lymphoma
Csaba Boedoer et al.
BLOOD (2013)
EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
Wendy Beguelin et al.
CANCER CELL (2013)
Phosphorylation of EZH2 Activates STAT3 Signaling via STAT3 Methylation and Promotes Tumorigenicity of Glioblastoma Stem-like Cells
Eunhee Kim et al.
CANCER CELL (2013)
EZH2 and CD79B Mutational Status Over Time in B-Cell Non-Hodgkin Lymphomas Detected by High-Throughput Sequencing Using Minimal Samples
Mauro Ajaj Saieg et al.
CANCER CYTOPATHOLOGY (2013)
Chromatin Regulator PRC2 Is a Key Regulator of Epigenetic Plasticity in Glioblastoma
Atsushi Natsume et al.
CANCER RESEARCH (2013)
Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition
Michael D. Amatangelo et al.
CELL CYCLE (2013)
Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth
Shivani Garapaty-Rao et al.
CHEMISTRY & BIOLOGY (2013)
SMARCB1 protein and mRNA loss is not caused by promoter and histone hypermethylation in epithelioid sarcoma
Gergo Papp et al.
MODERN PATHOLOGY (2013)
Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer
Woojin Kim et al.
NATURE CHEMICAL BIOLOGY (2013)
The Spectrum of SWI/SNF Mutations, Ubiquitous in Human Cancers
A. Hunter Shain et al.
PLOS ONE (2013)
Genetic heterogeneity of diffuse large B-cell lymphoma
Jenny Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
Sarah K. Knutson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer
Teruyuki Sato et al.
SCIENTIFIC REPORTS (2013)
Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
Joannah Score et al.
BLOOD (2012)
A Landscape of Driver Mutations in Melanoma
Eran Hodis et al.
CELL (2012)
A687V EZH2 is a gain-of-function mutation found in lymphoma patients
Christina R. Majer et al.
FEBS LETTERS (2012)
A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia
Camille Simon et al.
GENES & DEVELOPMENT (2012)
Identification of Somatic Mutations in Parathyroid Tumors Using Whole-Exome Sequencing
M. Kyle Cromer et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers
Ryan S. Lee et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes
Karolina Holm et al.
MOLECULAR ONCOLOGY (2012)
A somatic EZH2 mutation in childhood acute myeloid leukemia
T. Ernst et al.
LEUKEMIA (2012)
Chromatin-modifying enzymes as modulators of reprogramming
Tamer T. Onder et al.
NATURE (2012)
Novel mutations target distinct subgroups of medulloblastoma
Giles Robinson et al.
NATURE (2012)
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
Michael T. McCabe et al.
NATURE (2012)
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
Michael Krauthammer et al.
NATURE GENETICS (2012)
Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia
Panagiotis Ntziachristos et al.
NATURE MEDICINE (2012)
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)
Michael T. McCabe et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
Wei Qi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing
Jens G. Lohr et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
Kexin Xu et al.
SCIENCE (2012)
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2
Sharad K. Verma et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
Development and Validation of Reagents and Assays for EZH2 Peptide and Nucleosome High-Throughput Screens
Elsie Diaz et al.
JOURNAL OF BIOMOLECULAR SCREENING (2012)
PRAJA1 is a ubiquitin ligase for the polycomb repressive complex 2 proteins
Muhammad Zoabi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation
Damian B. Yap et al.
BLOOD (2011)
Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A
Anna M. Jankowska et al.
BLOOD (2011)
MiR-26a Inhibits Cell Growth and Tumorigenesis of Nasopharyngeal Carcinoma through Repression of EZH2
Juan Lu et al.
CANCER RESEARCH (2011)
Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker
Masashi Takawa et al.
CANCER SCIENCE (2011)
Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer
Bo Zhang et al.
CARCINOGENESIS (2011)
The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states
Tim J. Wigle et al.
FEBS LETTERS (2011)
Overexpression of enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy
Daisuke Sasaki et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Ovarian Cancer Stem Cell-Like Side Populations Are Enriched Following Chemotherapy and Overexpress EZH2
Sian Rizzo et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms
O. Abdel-Wahab et al.
LEUKEMIA (2011)
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Ryan D. Morin et al.
NATURE (2011)
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder
Yaoting Gui et al.
NATURE GENETICS (2011)
Down-Regulation of miR-101 in Endothelial Cells Promotes Blood Vessel Formation through Reduced Repression of EZH2
Michiel Smits et al.
PLOS ONE (2011)
EZH2 Codon 641 Mutations are Common in BCL2-Rearranged Germinal Center B Cell Lymphomas
Russell J. H. Ryan et al.
PLOS ONE (2011)
Temporal Dissection of Tumorigenesis in Primary Cancers
Steffen Durinck et al.
CANCER DISCOVERY (2011)
EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis
Irina Velichutina et al.
BLOOD (2010)
Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma
Nina Wagener et al.
BMC CANCER (2010)
Epigenetic Antagonism between Polycomb and SWI/SNF Complexes during Oncogenic Transformation
Boris G. Wilson et al.
CANCER CELL (2010)
Rhabdoid tumor: gene expression clues to pathogenesis and potential therapeutic targets
Samantha Gadd et al.
LABORATORY INVESTIGATION (2010)
Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies
H. Makishima et al.
LEUKEMIA (2010)
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
Ryan D. Morin et al.
NATURE GENETICS (2010)
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Thomas Ernst et al.
NATURE GENETICS (2010)
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas
Christopher J. Sneeringer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98
N. M. Alajez et al.
CELL DEATH & DISEASE (2010)
miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis
Michiel Smits et al.
ONCOTARGET (2010)
The Putative Tumor Suppressor microRNA-101 Modulates the Cancer Epigenome by Repressing the Polycomb Group Protein EZH2
Jeffrey M. Friedman et al.
CANCER RESEARCH (2009)
Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma
Roberta Ciarapica et al.
CELL CYCLE (2009)
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation
Tina Branscombe Miranda et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer
Gijs van Haaften et al.
NATURE GENETICS (2009)
Ezh2 requires PHF1 to efficiently catalyze h3 lysine 27 trimethylation in vivo
Kavitha Sarma et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer
Sooryanarayana Varambally et al.
SCIENCE (2008)
High-resolution profiling of histone methylations in the human genome
Artern Barski et al.
CELL (2007)
Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells
Jing Tan et al.
GENES & DEVELOPMENT (2007)
The polycomb group protein Suz12 is required for embryonic stem cell differentiation
Diego Pasini et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer
Outi R. Saramaki et al.
GENES CHROMOSOMES & CANCER (2006)
Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions
AP Bracken et al.
GENES & DEVELOPMENT (2006)
Control of developmental regulator's by polycomb in human embryonic stem cells
TI Lee et al.
CELL (2006)
EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast
IM Bachmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma
T Sudo et al.
BRITISH JOURNAL OF CANCER (2005)
SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex
R Cao et al.
MOLECULAR CELL (2004)
Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis
RHJ Breuer et al.
NEOPLASIA (2004)
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer
AP Bracken et al.
EMBO JOURNAL (2003)
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells
CG Kleer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Missense mutation and defective function of ATM in a childhood acute leukemia patient with MLL gene rearrangement
K Oguchi et al.
BLOOD (2003)
Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement
IH Su et al.
NATURE IMMUNOLOGY (2003)
Role of histone H3 lysine 27 methylation in polycomb-group silencing
R Cao et al.
SCIENCE (2002)
The polycomb group protein EZH2 is involved in progression of prostate cancer
S Varambally et al.
NATURE (2002)
Stem cells, cancer, and cancer stem cells
T Reya et al.
NATURE (2001)
Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice
CWM Roberts et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease
FM Raaphorst et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
